fda compounding semaglutide news september 2025 Drug compounders sue over declaration ending Wegovy shortage Novo Nordisk protects US patients

J Gen Physiol 110(3):217228

Her doctor reportedly told her that her binge eating and weight problems were "100% because [she] went on Ozempic." A 2025 review in eClinicalMedicine revealed that a substantial percentage of individuals with obesity who stop taking GLP-1s end up with larger waistlines and higher body mass indexes (BMIs) within 12 weeks

Zepbound tends to have a lower overall cost than Wegovy, on average

What Is the Tirzepatide Dosage Chart for Weight Loss

Many clients begin to notice changes within the first few weeks, while more significant results often appear after consistent treatment for several months

Strengths Affordable entry point No surprise telehealth fees Flexible, self-directed structure Trade-offs Out-of-pocket, no insurance Light on labs and monitoring Confirm medication sourcing carefully How GLP-1 Medications Work, and What Changed in 2026 A GLP-1 program is a medical weight-loss plan built around GLP-1 receptor agonists, drugs that mimic a natural gut hormone to reduce appetite and help regulate blood sugar